October 2006 Issue of MMM
The big four-oh is, for most of us, a tough one, as birthdays go.
The following 40 people are innovators, creative geniuses, entrepreneurs, leaders, thinkers, doers...legends.
A chronology of medical agencies, from the founding firms through to the holding companies that now own them
We asked numerous industry executives for their thoughts on the most memorable campaigns from the past four decades of medical advertising.
Get acquainted with some of medical marketing's hottest prospects. Expect to read a lot more about them in the next 40 years.
While the focus of activity in pharmaceutical R&D has shifted from mass-market primary care drugs to specialty products, there are signs the long freeze on ...
We asked seven of the industry's greats to reflect on the past of pharmaceutical promotion. Their candid answers have much to say about the present ...
Pharmaceutical companies have not always done a good job of proving their value to the public.
The pharmaceutical industry is dealing with a vast array of critical issues that this readership knows all too well.
The entire communications services industry--clients, media owners and agencies alike--faces unprecedented challenges.
Helping people live longer, healthier, more productive lives: that's what America's pharmaceutical research companies do on a daily basis.
Whether you are a mainstay of medical marketing with an encyclopedic knowledge to boot, or you are just starting out in the field and could ...
It's hard to believe that when this publication appeared 40 years ago, Tylenol was a relatively new product and the Medicare program was fresh out ...
My father is over 80 years old. To look at his bulging waistline and to hear about his history of heart disease is to wonder ...
Med Ed Report
The 1990s are regarded as one of the most positive decades for CME.
The stage is set for grantors and providers to continue evolving the quality of programming and their compliance with regulation during the next 40 years.
It was simpler in the days, before DTC and CME and a host of other acronyms crept into the mix.
The proliferation of available marketing channels--those targeting physicians as well as other audiences--has many in the medical publishing world convinced that the day of the ...
Pharma e-marketers have the Cold War to thank for their craft.
E-marketing has progressed into a way for marketers to differentiate themselves based on experience with their customers and as a viable means to be able ...
Lester Wunderman is credited with being the driving force behind direct marketing as it is known today, with his theories an integral part of the ...
As the mass marketing approach has become considered increasingly less effective, CRM and direct-to-patient initiatives are being thrust to the forefront of pharma marketers' efforts.
Claritin, approved in 1993 and launching DTC in 1995, wasn't the first big brand advertised to consumers, but it was the first really huge spender ...
After a period of soul-searching, a renewed commitment to self-regulation and a plague of doctors in TV ads, DTC seems to have survived the fallout ...
Corporate reputation can be a fickle thing—particularly in pharma.
Pharma marketers are seldom early adopters when it comes to cutting-edge promotional techniques and new technologies.
MM&M's 40th anniversary called to mind that one of my first articles for the magazine--not quite 40 years ago but close--was about the emergence of ...
What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.
A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.